Pay in 4 interest-free payments of $5.25 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
In vitro experiments with vascular endothelial cells showed that BPC 157 stimulated NO production, which in turn promoted cell migration
Regarding metabolic parameters, Cagrilintide treatment did not produce significant changes in HbA1c or fasting plasma glucose from baseline to week 26, while liraglutide 3.0 mg significantly improved both measures, consistent with its known glucose-lowering effects
Certificate of Analysis BPC-157 20mg COA Number 2607100581 Lot PH-bc20-0526 Reported 07/13/2026 Certificate of Analysis BPC-157 10mg COA Number 2607100576 Lot PH-bc10-0509 Reported 07/13/2026 Certificate of Analysis BPC-157 10mg COA Number 2606260188 Lot PH-bc10-0410 Reported 06/29/2026 Certificate of Analysis BPC-157 40mg COA Number 2606240317 Lot PH-bc40-0509 Reported 06/27/2026 Certificate of Analysis BPC-157 10mg COA Number 2606030039 Lot bc10-0309 Reported 06/05/2026 Certificate of Analysis BPC-157 20mg COA Number 2605280416 Lot PH-bc20-0109 Reported 05/30/2026 Certificate of Analysis BPC-157 40mg COA Number 2605060070 Lot PH-bc40-0201 Reported 05/08/2026 BPC-157 Peptide Specifications BPC-157 Chemical Structure Legal Disclaimer: BPC-157 is sold by Protide Health for laboratory research purposes only
The peptide is derived from a partial sequence of a larger protein found in human gastric juice called BPC, which was first isolated and characterized in the early 1990s
Your provider will help determine which formulation best aligns with your goals
In contrast, TIGAR overexpression or treatment with Fer-1, a ferroptosis inhibitor, significantly increases NADPH, GPX4, and GSH levels, reduces GSSG expression, and attenuates neuronal ferroptosis and neurological impairment
